Theracryf Share Discussion Threads

[thiopia] 24/10/2024 22:12:38

What an out of the blue deal with a Big Pharma can do !

[clocktower] 18/10/2024 16:36:07

Well someone seems to have taken a pretty big hit and have had enough but the MM seemed happy to take the 2.697 million on at .6175 which was higher than they took 150k on at 10.48am today as it was .6155 so maybe they have a buyer.

[clocktower] 18/10/2024 10:49:36

Can buy under .65 now

[clocktower] 18/10/2024 10:47:14

With only sells showing at .65 and a MM offering them ay the same level suggests they either have a lot more to unload or haqve a sellerat a lower level if they can find buyers.

[clocktower] 17/10/2024 15:49:52

Down again!

Little interest in these AIM stocks, that have directors that have had nothing to say about the dispute resolution progress or lack of it for many months, and do not buy any volume of shares in the market even though the share price has slumped further since the raise at 1p

Clearly some holders have thrown in the towel.

[xxproinvestorxx] 15/10/2024 14:34:15

I don't doubt that Stalicla will complete the series C fundraise. They are still expanding their experienced management team and I cannot see them giving back SFX-01 based on the fact that they have validated it for treatment of Phenotype 2 ASD, so they believe it is a promising candidate.

[xxproinvestorxx] 15/10/2024 14:31:50

Yes I saw that clocktower. Stalicla continue their attempt to secure their series C raise, where they want to raise between $60m and 75m. They did aim to have this round completed before the end of Q3, but that has past now. I think this is the real reason for the hold up on STP-2 progress. Stalicla want to secure the additional cash before given the $5.5m to Theracryf. I imagine things will move fast and STP-3 will going into Phase 2 once Stalicla have secured the funding.

[clocktower] 26/9/2024 11:16:26

Well if it was Black that kicked these sells he may have been the seller on the 19/09/2024 at 0.752 on which he would have made a few quid as there were a fair few buys at just under 0.70 but I cannot understand why someone with a huge holding would mess around, so it may not be him.

[dave4545] 26/9/2024 10:57:51

Sector selling again.

AGL tanked on results

Trls tanked on results.

Infact any Bio/Pharma announcing little turnover and big losses is seeing fresh lows

Deals are needed and big ones other wise everything gets smashed up in this bear market

And I hold here

[clocktower] 26/9/2024 10:20:45

Well those that seemed to have tried to ramp this up the other week seem to have been selling them back, having failed to get volumes moving up.

So back we go again with still no news.

Still those that bought in just under 0.70 will have covered there costs on some trades it but no longer, now the bid is 0.70 again.

[clocktower] 20/9/2024 14:08:06

Only one MM left on offer at .80

Seerms like a number of PI's buying in because it is at number 10 spot in gainers list in ADVFN.

If good news is coming next week this will jump rapidly I expect, as it has been over sold for a long time.

[hairballradical] 20/9/2024 09:31:33

The Ratcliffe Hotel and Spa seems to be attracting new money.

[clocktower] 20/9/2024 09:27:22

Although it seems rasther absurd, if I recall correctly, back around March/May this year Cavendish put a target of 11p on this stock. (please correct me if wrong)

We know broker notes are paid for by the companies in most cases but even if it were to return to the highs of 2022 at around 7p that would be a ten bagger from here but not reach the 8p level that a large sum of money was raised at previously.

[clocktower] 20/9/2024 08:57:27

Starting to look a little more than a ramp now.

Maybe this is the big turning point that had been dreamed of?

[xxproinvestorxx] 19/9/2024 19:57:08

Https://www.globenewswire.com/en/news-release/2024/09/19/2948879/0/en/Dr-Paulo-Fontoura-MD-PhD-joins-STALICLA-as-Chief-Scientific-and-Clinical-Development-Advisor.htmlFrom the 'about Stalicla' section of the report at the end."Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 24 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government."Note they have not named the second NDD asset, therefore we can presume it is not one of their own assets. The only other options are then STP2 or STPX. Since STPX is still in Phase 1, we are left with the front-runner as STP2!

[clocktower] 18/9/2024 11:50:54

Seeing the trades that have just shown up, I took a look at their linkedin page and I see they are attending BIO-Europe on 4/6.11.2024 and the notice of this was just released 1 day ago.

[clocktower] 18/9/2024 11:00:21

Just another ramp I expect and a few pals buying in to try to get it to spike and jump out.

Without news from the company that is positive it is only for pure gamblers at present, or long term holders that are ready to weather stormy seas, whom might get huge rewards.

I will continue to hold and live in hope on this one.

[ged5] 18/9/2024 10:37:14

Thanks to formerlyeasyp on the LSE forum.

No idea who this poster is and haven't verified the content by contacting the company but this sounded positive:-

"Thank you for contacting us. With regard to your questions:

We are still in active discussions with our partner Stalicla on dispute resolution. Inevitably disputes of this nature involving scientific and business matters can take considerable time. Rest assured we will update the market as soon as we have something concrete to say. On scientific progress, we announced on 10 July that our academic collaborators in University La Sapienza, Rome had published their paper on SFX-01 in the rare childhood cancer rhabdomyosarcoma in a prestigious, peer reviewed journal. Our paper on the results of our SFX-01 in our healthy volunteer study completed last year has been submitted for publication and we’ll alert the market when this is published. I encourage you to review the presentation and video of our R&D day in mid-June for a more detailed review of our portfolio by our team and external experts to see the status and prospects for these potentially market-leading medicines. All of our updates are available on our website: hxxps://theracryf.com/news-media/ Our guidance on cash runway remains unchanged from the publication of our annual results and AGM in June and July of this year. We have cash runway until the end of calendar year 2025 and remain in the top 30% of all European listed Biotech companies in terms of months of cash remaining (Rx Securities).



Please also note that we are active on X (formerly Twitter) and LinkedIn where updates that are not regulatory in nature are posted relatively frequently. On other matters we are completing the acquisition of Chronos Therapeutics and are actively seeking non-dilutive funding for those programmes.

Our shareholders are our lifeblood and I’d be happy to discuss these points in a call so please let me have some days and times that are convenient."

Sincerely,

[dave4545] 18/9/2024 10:02:24

See if a buy shows up at 10.16am as at 9.16am a mm moves up on the bid on no trade.

They tend not to give away free money so something should turn up then or at the close

[clocktower] 17/9/2024 13:30:18

Can buy at .673 now which I think is a new low.

[clocktower] 16/9/2024 16:21:06

Only AIM stocks on it's knees, look at the FTSE 100 much higher since Covid.

It seems to me now, that buying the broke company that HUW was associated with is just another whezz like his wish he could buy shares when they were very much higher than now.

Not one new deal in almost two years and no news of note.

[dave4545] 16/9/2024 16:02:44

Sorry penny markets